[HTML][HTML] Review of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine
The concept of PLGA-lipid hybrid nanoparticles arose as a motivation for developing drug
delivery systems with versatile physical and chemical properties, unequivocal therapeutic …
delivery systems with versatile physical and chemical properties, unequivocal therapeutic …
Development strategies and prospects of nano-based smart pesticide formulation
X Zhao, H Cui, Y Wang, C Sun, B Cui… - Journal of agricultural …, 2017 - ACS Publications
Pesticides are important inputs for enhancing crop productivity and preventing major
biological disasters. However, more than 90% of pesticides run off into the environment and …
biological disasters. However, more than 90% of pesticides run off into the environment and …
[HTML][HTML] PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: Effects of formulation parameters
KY Hernández-Giottonini, RJ Rodríguez-Córdova… - Rsc Advances, 2020 - pubs.rsc.org
This study presents the influence of the primary formulation parameters on the formation of
poly-DL-lactic-co-glycolic nanoparticles by the emulsification-solvent evaporation, and the …
poly-DL-lactic-co-glycolic nanoparticles by the emulsification-solvent evaporation, and the …
[HTML][HTML] Manufacturing techniques and surface engineering of polymer based nanoparticles for targeted drug delivery to cancer
The evolution of polymer based nanoparticles as a drug delivery carrier via pharmaceutical
nano/microencapsulation has greatly promoted the development of nano-and micro …
nano/microencapsulation has greatly promoted the development of nano-and micro …
Nanomedicine scale-up technologies: feasibilities and challenges
Nanomedicine refers to biomedical and pharmaceutical applications of nanosized cargos of
drugs/vaccine/DNA therapeutics including nanoparticles, nanoclusters, and nanospheres …
drugs/vaccine/DNA therapeutics including nanoparticles, nanoclusters, and nanospheres …
Designing, structural determination and biological effects of rifaximin loaded chitosan-carboxymethyl chitosan nanogel
SA Algharib, A Dawood, K Zhou, D Chen, C Li… - Carbohydrate …, 2020 - Elsevier
Due to the poor solubility and permeability of rifaximin (RFX), it is not effective against
intracellular pathogens although it shows strong activity against most bacteria. To develop …
intracellular pathogens although it shows strong activity against most bacteria. To develop …
[HTML][HTML] Solid lipid based nanocarriers: An overview/Nanonosači na bazi čvrstih lipida: Pregled
C Pardeshi, P Rajput, V Belgamwar, A Tekade… - Acta …, 2012 - sciendo.com
In the era of nanoparticulate controlled and site specific drug delivery systems, use of solid
lipids to produce first generation lipid nanoparticles, solid lipid nanoparticles (SLN), became …
lipids to produce first generation lipid nanoparticles, solid lipid nanoparticles (SLN), became …
Long-acting nanoparticle-loaded bilayer microneedles for protein delivery to the posterior segment of the eye
Abstract Treatment of neovascular ocular diseases involves intravitreal injections of
therapeutic proteins using conventional hypodermic needles every 4–6 weeks. Due to the …
therapeutic proteins using conventional hypodermic needles every 4–6 weeks. Due to the …
Microfluidic assembly of “Turtle-Like” shaped solid lipid nanoparticles for lysozyme delivery
F Sommonte, I Arduino, RM Iacobazzi, M Tiboni… - International Journal of …, 2023 - Elsevier
After two decades of research in the field of nanomedicine, nanoscale delivery systems for
biologicals are becoming clinically relevant tools. Microfluidic-based fabrication processes …
biologicals are becoming clinically relevant tools. Microfluidic-based fabrication processes …
Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition
Linagliptin (LGP), a novel anti-diabetic drug, is a DPP-4 inhibitor used in the treatment of
type II diabetes. One of the major disadvantages of LGP is its low oral bioavailability (29.5%) …
type II diabetes. One of the major disadvantages of LGP is its low oral bioavailability (29.5%) …